
FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
By Maya Yang
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications β which can facilitate weight loss β over a rare eye condition that could lead to sudden and permanent blindness. On Monday, the FDA announced that it is requiring all GLP-1 medications β including Novoβ¦
This story was published by The Guardian. Read the full article on their site.
Read the full story at theguardian.com(opens in a new tab)






